Aptabio Therapeutics Inc
293780
Company Profile
Business description
Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.
Contact
13, Heungdeok 1-ro, Giheung-gu
Tower 504, Gyeonggi-do
Yongin-Si16954
KORT: +82 7071520097
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
30
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.20 | 79.30 | 0.91% |
| CAC 40 | 7,804.67 | 40.83 | 0.53% |
| DAX 40 | 24,276.48 | 184.86 | 0.77% |
| Dow JONES (US) | 42,427.74 | 91.90 | -0.22% |
| FTSE 100 | 8,801.29 | 14.27 | 0.16% |
| HKSE | 23,654.03 | 141.54 | 0.60% |
| NASDAQ | 19,460.49 | 61.53 | 0.32% |
| Nikkei 225 | 37,747.45 | 300.64 | 0.80% |
| NZX 50 Index | 12,531.07 | 36.36 | 0.29% |
| S&P 500 | 5,970.81 | 0.44 | 0.01% |
| S&P/ASX 200 | 8,541.80 | 75.10 | 0.89% |
| SSE Composite Index | 3,376.20 | 14.23 | 0.42% |